FDA Accepts OLC Resubmission with June 2026 PDUFA Date Amidst Ongoing Legal Challenges

summarizeSummary

Unicycive Therapeutics received FDA acceptance for its OLC NDA resubmission with a PDUFA date of June 29, 2026, and raised $19.6 million via an ATM offering, while facing ongoing shareholder lawsuits and deprioritizing its UNI-494 program.

check_boxKey Events

• OLC NDA Resubmission Accepted with New PDUFA Date

  The FDA accepted the resubmission of the New Drug Application (NDA) for oxylanthanum carbonate (OLC), setting a new Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2026. This follows a Complete Response Letter (CRL) issued in June 2025 due to deficiencies at a third-party manufacturing vendor, not related to clinical or safety data.

• Significant Capital Raise via ATM Program

  Subsequent to December 31, 2025, the company sold 3,123,537 shares of common stock at an average price of $6.51 per share through an At-The-Market (ATM) offering, generating approximately $19.6 million in net proceeds. This represents a significant capital infusion for the company.

• Ongoing Shareholder Lawsuits

  The company is a defendant in a shareholder class action lawsuit (filed August 2025) and two derivative complaints (filed October/November 2025), alleging material misrepresentations and breaches of fiduciary duty related to OLC's manufacturing and approval prospects. A motion to dismiss the amended complaint was filed on March 13, 2026.

• UNI-494 Development Deprioritized

  Despite receiving Orphan Drug Designation in February 2024 for the prevention of Delayed Graft Function (DGF) in kidney transplantation, the company has decided to deprioritize further development of UNI-494 for the time being, shifting focus to OLC commercialization.

auto_awesomeAnalysis

Unicycive Therapeutics' annual report highlights a critical regulatory milestone for its lead product candidate, oxylanthanum carbonate (OLC), with the FDA accepting its NDA resubmission and setting a new PDUFA date of June 29, 2026. This provides a clear path towards potential market approval and commercialization, a significant positive for a clinical-stage biotech. The company also bolstered its financial position by raising $19.6 million in net proceeds through an At-The-Market (ATM) offering subsequent to year-end, extending its operational runway. However, these positive developments are tempered by ongoing shareholder class action and derivative lawsuits alleging misrepresentations related to OLC's manufacturing and approval prospects, introducing a notable legal risk. Additionally, the decision to deprioritize UNI-494 development, despite its Orphan Drug Designation, indicates a focused but narrowed pipeline strategy. Investors will closely monitor the upcoming PDUFA decision and the progress of the legal proceedings.